The Role of Glucagon-Like Peptide-1 Receptor Agonists in Coronary Artery Diseases and Their Potential Mechanisms
- Status
- Not yet recruitingResults none
- Why it is watched
- non-weight indication: cardiovascular
- Who it enrolls
- age 20 Years to no upper limit; no BMI minimum stated; conditions: Glucagon-Like Peptide-1 Receptor Agonists; Type 2 Diabetes; Coronary Arterial Disease (CAD)
- Interventions
- Semaglutide 1.0 mg; Semaglutide 0.5 mg
- Conditions
- Glucagon-Like Peptide-1 Receptor Agonists; Type 2 Diabetes; Coronary Arterial Disease (CAD)
- Phase and size
- Phase 4 · 60 participants
- Dates
- Start 2025-10-01
Primary completion 2028-07-31 - Sponsor
- Taipei Veterans General Hospital, Taiwan (Other gov)
- Last checked
- Sep 13, 2026
01Endpoints
What the trial will measure
- change of Time-in-range (%)From enrollment to the end of treatment at 24 weeks
- change of HbA1cFrom enrollment to the end of treatment at 24 weeks
- change of Flow-Mediated Dilatation (FMD)From enrollment to the end of treatment at 24 weeks
02Eligibility
Who can take part
Inclusion Criteria: 1. adults (\>=20 years old), 2. Type 2 Diabetes with coronary arterial disease underwent angioplasty within 3 months with SGLT2 inhibitors - Exclusion Criteria: 1. age\<20 years old, 2. pregnant women, 3. eGFR\<30 ml/min/1.73m2, 4. received GLP-1 agonist in the recent 3 months -
03Change log
Registry changes
No changes recorded since the trial was added.